[1] Shreve PD, Anzai Y, Wahl RL. Pitfall in oncologic diagnosis with FDG PET imaging:physiologic and benign variants[J].Radiographics, 1999, 19(1):61-77.
[2] Brigid GA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography:normal variations, pitfalls, and technical considerations[J]. Am J Roentgenol, 1997,169:1675-1680.
[3] Miraldi F, Vesselle H, Faulhaber PF, et al. Elimination of artifactual accumulation of FDO in PET imaging of colorectal cancer[J]. Clin Nucl Med, 1998, 23:3-7.
[4] Conti PS, Durshi JM, Singer PA, et ah Incidence of thyroid gland uptake of F-18 FDG in cancer patients[J]. Radiology,1997, 205:220.
[5] Bar-Shalom R. Muscle uptake of 18-fluorine fluoro deoxyglucose[J]. Semin Nucl Med, 2000, 30(4):306-309.
[6] Engel H, Steinert H, Buck A, et al. Whole-body PET:Physiological and artifactual fluorodeoxyglucose accumulations[J]. J Nucl Med, 1996, 37:441-446.
[7] Mossberg KA, Mommession JI, Taegtmeyer H. Skeletal muscle glucose uptake during short-term contractile activity in vivo:effect of prior contractions[J]. Metabolism, 1993, 42:1609-1616.
[8] Kostakoglu L, Wong JCH, Barrington SF, et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG[J]. J Nucl Med, 1996, 37:1771-1773.
[9] Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine 18-FDG:effect on oral diazepam[J]. J Nucl Med, 1996, 37:1127-1129.
[10] 赵军.18F-FDG PET诊断肿瘤应考虑的几个问题[J].国外医学·放射医学核医学分册,1999,23(6):241-245.
[11] Sugawara Y, Fisher SJ, Zasadny KR, et al. Pre-clinic and clinic studies of bone marrow uptake of fluorine-18-fluo-rodeoxyglucose with or without granulocyte colony-stimulating factor during chemotheraphy[J]. J Clin Oncol, 1998,16:173-180.
[12] Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum:mormal anatomy, variants,pathologic conditions, and strategies to avoid diagnostic pitfalls[J]. Radiographics, 1998, 18:805-823.
[13] Kosuda S, Fisher S, Kison PV, et al. Uptake of 2-deoxy-2-18F-fluoro-D-glucose in normal testis:retrospective PET study and animal experiment[J]. Ann Nucl Med, 1997, 11:195-199.
[14] Chander S, Meltzer CC, Mccook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography[J]. Clin Nucl Med, 2002, 27(1), 22-24.
[15] Meyer M, Gast T, Raja S, et al. Increased F-18 FDG accumulation in an acute fracture[J]. Clin Nucl Med, 1994, 19:13-14.
[16] Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sacoidosis[J]. J Nucl Med,1994, 35:1647-1649.
[17] Strauss LG. Fluorine-18-deoxyglucose and false-positive results:a major problem in the diagnostics of oncological patients[J]. Eur J Nucl Med, 1996, 23:1409-1415.
[18] Kim SK, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET[J]. Radiographics, 1999, 19:61-77.
[19] Yun MJ, Jang SY, Cucchiara A, et al. 18F-FDG uptake in the large arteries:Acorrelation study with the atherogenic risk factors[J]. Semin Nucl Med, 2002, 32(1):70-76.
[20] Paul G, Kluetz BS, Carolyn CM, et al. Combined PET/CT imaging in oncology impact on patient management[J]. Clin Positronimag, 2000, 3(6):223-230.
[21] Inagaki H, Kato T, Tadokoro M, et al. Interactive fusion of three-dimensional imagines of upper abdominal CT and FDG PET with no body surface markers[J]. Radiat Med, 1999, 17:155-163.
[22] Zhuang HM, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation[J]. Semin Nucl Med, 2002, 32(1):47-59.
[23] Mamede M, Saga T, Ishimori T, et al. Differential uptake of F-18-FDG in experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of steroid pretreatment on tumor uptake[J]. J Nucl Med, 2001,42:1172.
[24] Zhuang HM, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes[J]. J Nucl Med, 2001, 42(9):1412-1417.
[25] Matties A, Hickeson M, Cuchiara A, et al. Dual time point 18F-FDG PET for the evaluation of puimonary nodules[J]. J Nucl Med, 2002, 43(7):871-875.
[26] Nakamoto Y, Higashi T, Sakahara H, et al. Delayed FDGPET scan for the differentiation between malignant and benign lesions[J]. J Nucl Med, 1999, 40:247.
[27] Herzog HR, Borner AR, Weckesser M, et al. Delayed scan time for FDG PET in breast cancer[J]. J Nucl Med, 1999,40:140.
[28] Ishizu K, Nakamura S, Shiozaki T, et al. Increasing rate of FDG uptake from early to delayed PET images in lung tumors[J]. J Nucl Med, 2000, 41:76.